What Did You Actually Lose? Fat Mass, Lean Mass, and Muscle During GLP-1 Weight Loss

When the number on the scale falls, it is natural to summarize the result with one sentence: “I lost weight.” But body weight is a total. It does not tell you which tissues changed, whether your strength changed, or how well you are functioning.

During substantial weight loss—including weight loss associated with reduced-calorie diets, bariatric procedures, and medications—the body can lose both fat mass and lean mass. The proportions vary among people and studies. Understanding those terms is the first step toward interpreting weight loss more accurately.

Body weight is more than body fat

A body-composition assessment commonly separates total mass into two broad categories:

Lean mass includes more than skeletal muscle. It also includes body water, organs, connective tissue, and other non-fat components. Bone may be reported separately depending on the method.

That distinction matters. A study reporting a reduction in lean mass is not necessarily reporting an equal reduction in skeletal muscle. Hydration and glycogen changes can affect lean-mass estimates, especially during active weight loss. Body-composition tools estimate tissue compartments; they do not directly count every pound of muscle.

What have major treatment trials observed?

Two body-composition substudies help illustrate why the answer is more nuanced than many headlines suggest.

STEP 1 exploratory analysis

Semaglutide and body composition

In an exploratory DXA analysis, 140 participants underwent body-composition assessment. Among participants receiving semaglutide 2.4 mg, total fat mass decreased by 19.3% and total lean body mass decreased by 9.7% from baseline. Because fat mass fell more, the proportion of body weight represented by lean mass increased.¹

140participants assessed

−19.3%total fat mass

−9.7%total lean mass

Important limitation: This was an exploratory subgroup analysis, not a measurement of every STEP 1 participant.

SURMOUNT-1 DXA substudy

Tirzepatide and body composition

Among 160 participants with baseline and Week 72 measurements, the pooled tirzepatide group had average reductions of 21.3% in body weight, 33.9% in fat mass, and 10.9% in lean mass. Investigators estimated that approximately 75% of the lost weight was fat mass and 25% was lean mass.² The paper subsequently received a published correction, which should be read with the original report.³

−21.3%body weight

−33.9%fat mass

−10.9%lean mass

Important limitation: This was a relatively small substudy with post hoc analyses. The averages do not predict an individual's result.

DXA reports lean tissue—not a direct measurement of skeletal-muscle quality, strength, or physical function. These studies also evaluated particular populations, treatments, doses, durations, and accompanying lifestyle programs.

Is lean-mass loss unique to GLP-1 therapy?

No. Loss of some fat-free or lean tissue is a recognized feature of weight reduction more generally.

When energy intake falls and body weight decreases, the body adapts across multiple tissues. The amount and clinical importance of lean-tissue change can be influenced by starting body composition, age, sex, rate and magnitude of weight loss, dietary intake, activity, illness, and the measurement method.

How did body composition, strength, physical function, nutrition, symptoms, and overall health change together?

That question is more useful than treating every pound of lean mass as identical—or assuming that the scale alone describes success.

Why strength and function matter

Muscle is important for movement, balance, daily tasks, and independence. But a body-composition number cannot describe all aspects of muscle performance.

Two people with similar measured lean mass can differ in strength and function. Someone may also lose some measured lean mass during substantial weight reduction while improving mobility, cardiometabolic health, or relative body composition.

No measurement is perfect. DXA and consumer bioelectrical-impedance devices can both be affected by hydration and testing conditions. Consistent methods and contextual interpretation are generally more useful than treating one reading as absolute truth.

What can support lean tissue and function?

The strongest general framework combines appropriate nutrition with physical activity—especially resistance exercise—rather than relying on one isolated tactic.

A 2025 systematic review and meta-analysis of 25 randomized trials examined resistance exercise during diet-induced weight loss in adults with overweight or obesity. Compared with diet-only programs, adding resistance exercise attenuated fat-free-mass loss, increased fat-mass loss, and improved muscular strength, although certainty differed by outcome.⁴

A separate review of 114 trials also found resistance-based exercise useful across multicomponent weight-management programs.⁵ These findings come mainly from weight-loss research broadly, not exclusively from people using GLP-1–based medications. They support resistance training as a general foundation, but they do not guarantee complete preservation of lean mass in every person.

Current U.S. guidance recommends muscle-strengthening activity on at least two days each week in addition to aerobic activity.⁶ This is population guidance, not a personalized exercise prescription.

Nutrition matters as well. A 2025 joint advisory from four professional organizations emphasizes nutritional adequacy, sufficient protein, strength training, and assessment of muscle strength, function, and body composition where appropriate during GLP-1 therapy.⁷ The advisory also notes that protein alone is unlikely to be an adequate muscle-preservation strategy without structured resistance or strength training.

Protein needs vary with body size, age, kidney function, health status, total energy intake, and activity. A registered dietitian or other qualified clinician can help translate general principles into an individualized plan.

Questions to discuss with your healthcare team

Key takeaways

• Weight loss can include both fat mass and lean mass.
• Lean mass is not synonymous with skeletal muscle.
• In the cited semaglutide and tirzepatide substudies, fat mass decreased more than lean mass.
• Individual results vary, and body-composition substudies have important limitations.
• Strength, function, nutrition, symptoms, and health outcomes add context the scale cannot provide.
• Resistance exercise and appropriate nutrition are complementary foundations; neither guarantees complete preservation of lean mass.

References

1. Wilding JPH, Batterham RL, Calanna S, et al. Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study. Journal of the Endocrine Society. 2021;5(Suppl 1):A16-A17. Read the study.
2. Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study. Diabetes, Obesity and Metabolism. 2025;27(5):2720-2729. View on PubMed.
3. Correction to “Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study.” Diabetes, Obesity and Metabolism. 2025;27(11):6823. View correction.
4. Binmahfoz A, Dighriri A, Gray C, Gray SR. Effect of resistance exercise on body composition, muscle strength and cardiometabolic health during dietary weight loss. BMJ Open Sport & Exercise Medicine. 2025;11(3):e002363. Read the review.
5. Lopez P, Taaffe DR, Galvão DA, et al. Resistance training effectiveness on body composition and body weight outcomes in individuals with overweight and obesity. Obesity Reviews. 2022;23(5):e13428. View on PubMed.
6. U.S. Department of Health and Human Services. Physical Activity Guidelines for Americans: Top 10 Things to Know. View official guidance.
7. Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory. Obesity. 2025;33(8):1475-1503. Read the advisory.